Barry Riskin, MD
Neurology · Bloomington, ILNPI 1326233271
Payments from drug & device makers
Across 327 payments — averaging $312.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$39K
- Sanofi$34K
- Eisai Inc.$16K
- Pfizer$5K
- Eli Lilly$4K
- AbbVie$389
- plus $3K from 32 others
Across 1 payment — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Consulting fees$12,80513%
- Speaking & faculty fees$72,41574%
- Travel & lodging$6,5267%
- Food & beverage$6,1476%
- Education$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 81 | $39,472 |
| Sanofi | 33 | $34,405 |
| Eisai Inc. | 24 | $16,032 |
| Pfizer | 18 | $4,768 |
| Eli Lilly | 2 | $3,925 |
| AbbVie | 22 | $389 |
| Supernus Pharmaceuticals, Inc. | 15 | $385 |
| EMD Serono, Inc. | 22 | $363 |
| MDD US Operations, LLC | 8 | $232 |
| AstraZeneca | 4 | $230 |
| Novartis | 13 | $225 |
| Amneal Pharmaceuticals LLC | 9 | $175 |
| Teva Pharmaceuticals USA, Inc. | 6 | $132 |
| Mallinckrodt Hospital Products Inc. | 7 | $128 |
| Lilly USA, LLC | 7 | $124 |
| Genentech USA, Inc. | 6 | $117 |
| Argenx US, Inc. | 5 | $97 |
| Avion Pharmaceuticals | 6 | $96 |
| UCB, Inc. | 4 | $91 |
| Octapharma USA, Inc. | 1 | $75 |
| Kyowa Kirin, Inc. | 4 | $69 |
| Corium, LLC | 4 | $64 |
| Amgen(2 entities) | 4 | $52 |
| Optinose US, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Bristol Myers Squibb | 3 | $46 |
| Lundbeck LLC | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $35 |
| GE HealthCare | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,038 in reported general payments places this provider in the 85th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 184 | $1,011,813 |
| RytaryCarbidopa/Levodopa | 127 | $189,048 |
| GocovriAmantadine Hcl | 17 | $75,896 |
| Nurtec OdtRimegepant Sulfate | 29 | $51,373 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 522 | $14,110 |
| UbrelvyUbrogepant | 13 | $12,839 |
| NamzaricMemantine Hcl/Donepezil Hcl | 15 | $12,599 |
| Emgality PenGalcanezumab-Gnlm | 14 | $10,484 |
| Memantine Hcl | 375 | $9,298 |
| Donepezil Hcl | 216 | $2,460 |
| Pyridostigmine Bromide | 33 | $1,920 |
| Gabapentin | 45 | $1,725 |
| Pregabalin | 32 | $1,719 |
| Primidone | 50 | $1,591 |
| Baclofen | 76 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $39,472 | $1,011,813184 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $175 | $190,967160 claims |
| MDD US Operations, LLCGocovri | $232 | $75,89617 claims |
| PfizerNurtec Odt | $4,768 | $51,37329 claims |
| AbbVieUbrelvy, Namzaric | $389 | $25,43928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 790 neurology providers in Illinois.
Other neurology in Bloomington
- Daniel WynnNorthbrook$13.9M
- Concetta ForchettiElk Grove Village$8.5M
- Tatyana SimuniChicago$3.5M
- Danny BegaChicago$2.8M
- Thomas AlaSpringfield$2.4M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Anthony RederBurr Ridge$1.6M
- Dusan StefoskiChicago$1.5M
- Kourosh RezaniaChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.